An Environmental Scientist and an Educator Highlight Navajo Efforts to Balance Tradition with Scientific Priorities

An Environmental Scientist and an Educator Highlight Navajo Efforts to Balance Tradition with Scientific Priorities

Navajo Nation's Monument Valley Park, Arizona.

Gabriel Reilich

This article is part of the magazine, "The Future of Science In America: The Election Issue," co-published by LeapsMag, the Aspen Institute Science & Society Program, and GOOD.

The global pandemic has made it impossible to ignore the stark disparities that exist within American communities. In the past months, journalists and public health experts have reminded us how longstanding systemic health and social inequities have put many people from racial and ethnic minority groups at increased risk of getting sick and dying from COVID-19. Still, the national dialogue noticeably lacks a general awareness of Indigenous people's needs and priorities, especially in the scientific realm.

To learn more about some of the issues facing often-overlooked Indigenous tribal communities, we sought the perspectives of two members of the Navajo Nation: Nonabah Lane, Director of Development of New Mexico Projects at Navajo Power and the founder of Navajo Ethno-Agriculture, a farm that teaches Navajo culture through traditional farming and bilingual education; and Elmer Guy, Ph.D., president of Navajo Technical University, the first university to be established forty years ago on the Navajo Nation that today stands as a premier institution of higher education focusing on a balance between science and technology and traditional culture.

Keep Reading Keep Reading
Daniel Cappello
Daniel Cappello is a writer based in New York City. He has worked as an editor for The New Yorker, Quest, George, and Harvard Current magazines, and his writing, on subjects from health and science to politics, culture, travel, and the arts, has appeared in The New York Times and Architectural Digest. Daniel supports cancer fundraising, research, and education, with a focus on rare cancers and sarcomas. At Memorial Sloan Kettering Cancer Center, he serves as a mentor for Visible Ink, a program in which cancer patients are able to express their experiences through writing.
Get our top stories twice a month
Follow us on
Patients, family voice hope and relief as FDA gives only its third-ever drug approval for ALS

On Sept. 29, the FDA approved Relyvrio, a new drug for ALS, even though a study of 137 ALS patients did not result in “substantial evidence” that Relyvrio was effective.

Adobe Stock

At age 52, Glen Rouse suffered from arm weakness and a lot of muscle twitches. “I first thought something was wrong when I could not throw a 50-pound bag of dog food over the tailgate of my truck—something I use to do effortlessly,” said the 54-year-old resident of Anderson, California, about three hours north of San Francisco.

In August, Rouse retired as a forester for a private timber company, a job he had held for 31 years. The impetus: amyotrophic lateral sclerosis, or ALS, a progressive neuromuscular disease that is commonly known as Lou Gehrig’s disease, named after the New York Yankees’ first baseman who succumbed to it less than a month shy of his 40th birthday in 1941. ALS eventually robs an individual of the ability to talk, walk, chew, swallow and breathe.

Keep Reading Keep Reading
Susan Kreimer
Susan Kreimer is a New York-based freelance journalist who has followed the landscape of health care since the late 1990s, initially as a staff reporter for major daily newspapers. She writes about breakthrough studies, personal health, and the business of clinical practice. Raised in the Chicago area, she holds a B.A. in Journalism/Mass Communication and French from the University of Iowa and an M.S. from the Columbia University Graduate School of Journalism.
Friday Five Podcast: New drug may slow the rate of Alzheimer's disease

On September 27, pharmaceuticals Biogen and Eisai announced that their drug, lecanemab, can slow the rate of Alzheimer's disease, according to a clinical trial. Today's Friday Five episode covers this story and other health research over the month of September.

Adobe Stock

The Friday Five covers important stories in health and science research that you may have missed - usually over the previous week, but today's episode is a lookback on important studies over the month of September.

Most recently, on September 27, pharmaceuticals Biogen and Eisai announced that a clinical trial showed their drug, lecanemab, can slow the rate of Alzheimer's disease. There are plenty of controversies and troubling ethical issues in science – and we get into many of them in our online magazine – but this news roundup focuses on scientific creativity and progress to give you a therapeutic dose of inspiration headed into the weekend and the new month.

Keep Reading Keep Reading
Matt Fuchs

Matt Fuchs is the editor-in-chief of Leaps.org. He is also a contributing reporter to the Washington Post and has written for the New York Times, Time Magazine, WIRED and the Washington Post Magazine, among other outlets. Follow him on Twitter @fuchswriter.